Efficacy of Evolocumab in Monogenic vs Polygenic Hypercholesterolemia
Background: Inhibitors of proprotein convertase subtilisin kexin 9 are indicated in Canada for treatment of patients with familial hypercholesterolemia (FH). Classically, FH is considered to be a monogenic condition caused by rare pathogenic mutations; however, some patients have hypercholesterolemi...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-05-01
|
| Series: | CJC Open |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589790X19300137 |